טוען...
Targeting Regorafenib-induced Toxicity through Inhibition of Gut Microbial β-Glucuronidases
Regorafenib (Stivarga) is an oral small molecule kinase inhibitor used to treat metastatic colorectal cancer, hepatocellular carcinomas, and gastrointestinal stromal tumors. Diarrhea is one of the most frequently observed adverse reactions associated with regorafenib. This toxicity may arise from th...
שמור ב:
| הוצא לאור ב: | ACS Chem Biol |
|---|---|
| Main Authors: | , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7254866/ https://ncbi.nlm.nih.gov/pubmed/31663730 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acschembio.9b00663 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|